相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1413
已完成
4
50.0%
Unknown
4
50.0%
暂无批准数据
- ki:elements' Speech Biomarker for Cognition (SB-C) successfully detected cognitive impairment and Alzheimer's disease pathology through automated phone calls in a study of 736 participants across five European cohorts. - The AI voice agent demonstrated significant diagnostic accuracy, identifying amyloid-beta positivity with an AUC of up to 0.74 and phosphorylated tau 181 positivity with an AUC of up to 0.82. - The 10-minute multilingual assessment offers pharmaceutical companies a validated pre-screening tool to identify biomarker-positive candidates before expensive invasive procedures like lumbar punctures or PET scans. - The technology is currently deployed in multiple Alzheimer's clinical trials and shows strong convergent validity with established cognitive assessments like MMSE and PACC-5.
- Panakeia's PANProfiler Colorectal (MSI/MMR) software demonstrated 93.83% agreement with standard laboratory testing in the largest real-world, multi-site validation study of AI molecular profiling to date. - The AI software successfully returned results on 86.55% of cases across 1,243 colorectal cancer patients from three UK healthcare institutions, delivering molecular biomarker analysis in minutes rather than weeks. - Published in npj Digital Medicine, the study addresses critical gaps in molecular testing access, with national audits showing substantial proportions of eligible patients experience testing delays of several weeks. - The UKCA-marked software is now deployed in UK hospitals and selected for the MHRA's AI Airlock programme, positioning it for broader healthcare system implementation.
- Pneumagen's intranasal antiviral drug Neumifil demonstrated clinically significant reductions in both incidence and severity of symptomatic influenza infections in a Phase 2 controlled human infection model study. - The broad-spectrum antiviral, developed using proprietary GlycoTarge technology, works by directly binding to viral pathogens and preventing their entry into host cells. - Based on these positive results presented at the American Thoracic Society meeting, Pneumagen plans to advance Neumifil into further clinical studies, including evaluation for reducing COPD exacerbations in high-risk patients.
